R. Eusebio

发表

Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

D. Reid, R. Hughes, R. Laan, 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid‐Induced Osteoporosis in Men and Women: A Randomized Trial

D. Reid, R. Hughes, R. Laan, 2000 .

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

P. Delmas, R. Recker, C. Benhamou, 2012, Calcified Tissue International.

Paget's disease of bone: reduction of disease activity with oral risedronate.

D. Hosking, A. Chines, R. Eusebio, 1998, Bone.

Risedronate Gastrointestinal Absorption Is Independent of Site and Rate of Administration

R. Eusebio, P. Bekker, M. Clay, 1998, Pharmaceutical Research.

Dose‐Proportional Pharmacokinetics of Risedronate on Single‐Dose Oral Administration to Healthy Volunteers

N. Sacco-Gibson, R. Eusebio, G. Thompson, 2000, Journal of clinical pharmacology.

Effect of renal function on risedronate pharmacokinetics after a single oral dose.

R. Eusebio, G. Thompson, J. S. St. Peter, 2000, British journal of clinical pharmacology.

Risedronate in the Treatment of Paget's Disease of Bone: An Open Label, Multicenter Study

Jacques P. Brown, R. Altman, E. Siris, 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

The erosion protection efficacy of a stabilized stannous fluoride dentifrice: An in situ randomized clinical trial.

R. Eusebio, T. He, N. West, 2019, American journal of dentistry.

Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.

T. Clemens, R. Eusebio, F. Singer, 1998, The Journal of clinical endocrinology and metabolism.

Randomized in situ clinical trial evaluating erosion protection efficacy of a 0.454% stannous fluoride dentifrice

R. Eusebio, T. He, N. West, 2019, International journal of dental hygiene.

Erosion protection efficacy of a 0.454% stannous fluoride dentifrice versus an arginine-containing dentifrice.

R. Eusebio, T. He, N. West, 2018, American journal of dentistry.

Willberg, A. (2019). Randomized In Situ Clinical Trial Evaluating Erosion Protection Efficacy of a 0.454% Stannous Fluoride Dentifrice: Erosion

R. Eusebio, N. Claydon, J. Seong, 2019 .

Assessment of the Effects of a Novel Stabilized Stannous Fluoride Dentifrice on Gingivitis in a Two-Month Positive-Controlled Clinical Study.

R. Eusebio, T. He, C. Goyal, 2017, The Journal of clinical dentistry.

Site-specific prevalence and cell densities of selected microbes in the lower reproductive tract of menstruating tampon users.

R. Eusebio, R. W. Berg, A. Hochwalt, 2002, Infectious diseases in obstetrics and gynecology.

Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.

C. Hayes, A. Chines, R. Eusebio, 2000, Bone.

Isolated free fluid on abdominal computerized tomographic scan: an indication for surgery in blunt trauma patients?

L. Jacobs, R. Eusebio, S. Gabram, 1994, Connecticut medicine.

Once‐Weekly Risedronate in Men With Osteoporosis: Results of a 2‐Year, Placebo‐Controlled, Double‐Blind, Multicenter Study

S. Boonen, P. Delmas, E. Orwoll, 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Risedronate Pharmacokinetics and Intra- and Inter-Subject Variability Upon Single-Dose Intravenous and Oral Administration

W. H. Barr, R. Eusebio, G. Thompson, 2001, Pharmaceutical Research.

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.

S. Boonen, P. Delmas, C. Benhamou, 2008, Bone.

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.

S. Boonen, E. Orwoll, D. Wenderoth, 2012, Bone.

Different definitions of remission for ulcerative colitis result in large variations of clinical outcome scores: P-0057

P. Higgins, R. Eusebio, S. Kane, 2007 .

A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data

P. Delmas, R. Recker, C. Benhamou, 2012, Calcified Tissue International.

Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data

S. Boonen, P. Delmas, C. Roux, 2012, Osteoporosis International.

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results

P. Delmas, R. Recker, C. Benhamou, 2008, Osteoporosis International.

Comparative Antiplaque Effect of Two Antimicrobial Dentifrices: Laboratory and Clinical Evaluations.

R. Eusebio, T. He, L. Friesen, 2017, The Journal of Clinical Dentistry.

Randomized In Situ Clinical Trial Evaluating Erosion Protection Efficacy of a 0.454% Stannous Fluoride Dentifrice: Erosion protection from SnF2 dentifrice.

R. Eusebio, N. Claydon, J. Seong, 2019 .